Alnylam Pharmaceuticals, Inc. vs Datadog Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Datadog Inc trades at $240.71 (market cap $88.61B). The key difference: Datadog Inc is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Datadog Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DDOG | |
|---|---|---|
Market Cap | $29.60B | $88.61B |
Sector | Health | Technology |
52-Week High | $491.22 | $288.15 |
52-Week Low | $205.48 | $102.62 |
Enterprise Value | $27.56B | $84.90B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Datadog (DDOG) trades at $241.00, down 7.58% amid a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. The stock shows elevated valuation ratios (P/E 493.56, P/S 22.83) but maintains robust revenue growth (36% YoY in Q2) and a high gross profit margin of 79.51%. Recent insider selling and mixed technical indicators contrast with an 83% analyst buy rating.
Outlook: Long-term growth driven by AI demand and net revenue retention above 120% supports upside to the $288.55 consensus target. Risks include valuation sensitivity, customer concentration, and execution pressure. The stock presents a growth opportunity with volatility near-term.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →